NX Prenatal has partnered with world-class leaders in the fields of biomedical research, proteomics, and clinical molecular diagnostics to develop its groundbreaking technology.
AmericanBio is an ISO 13485, ISO 9001 and cGMP certified provider and innovator of branded biochemicals, reagents, and contract manufacturing services. NX Prenatal has partnered with AmericanBio to enable the high volume production of proprietary sample prep kits and reagents to support NX Prenatal’s planned launch of its NeXosome Preterm Birth Risk Assay and related products.
Thermo Fisher Scientific
Thermo Fisher is a world leader in proteomics, and its liquid chromatography-mass spectrometry (LC-MS) instrumentation is an enabling technology for the new era of personalized medicine. Thermo Fisher and NX Prenatal have established and are further optimizing integrated workflows to enable high volume clinical mass spec proteomic evaluation of plasma samples enriched for exosomes via the NeXosome® platform.
NXPN has entered a strategic collaboration with Milu Labs, whose mission is to become the leading diagnostics company in Asia with a focus on maternal fetal medicine and women’s health. Milu Labs plans to commercialize multiple best-in-class technologies to enable a new era of personalized medicine for maternal-fetal health in the region. The objective of the collaboration is to commercialize NXPN's lead Preterm Birth Risk test in select Asian markets.
Please contact us at for inquiries into our contract research services to accelerate your research via the use of our NeXosome Platform to evaluate maternal-fetal diagnostics questions.